In situ apolipoprotein E-enriched corona guides dihydroartemisinin-decorating nanoparticles towards LDLr-mediated tumor-homing chemotherapy

Publication date: Available online 5 July 2019Source: Asian Journal of Pharmaceutical SciencesAuthor(s): Zhenbao Li, Jiaojiao Zhu, Yongqi Wang, Mei Zhou, Dan Li, Shunzhe Zheng, Cong Luo, Huicong Zhang, Lu Zhong, Wei Li, Jian Wang, Shuangying Gui, Biao Cai, Yongjun Wang, Jin SunAbstractThe therapeutic efficiency of active targeting nanoparticulate drug delivery systems (nano-DDS) is highly compromised by the plasma proteins adsorption on nanoparticles (NPs) surface, which significantly hinders cell membrane receptors to recognize the designed ligands, and provokes the off-target toxicity and rapid clearance of NPs in vivo. Herein, we report a novel dihydroartemisinin (DHA)-decorating nano-DDS that in situ specifically recruits endogenous apolipoprotein E (apoE) on the NPs surface. The apoE-anchored corona is able to prolong PLGA-PEG2000-DHA (PPD) NPs circulation capability in blood, facilitate NPs accumulating in tumor cells by the passive enhanced permeability and retention (EPR) effect and low-density lipoprotein receptor (LDLr)-mediated target transport, and ultimately improve the in vivo antitumor activity. Our findings demonstrate that the strategy of in situ regulated apoE-enriched corona ensures NPs an efficient LDLr-mediated tumor-homing chemotherapy.Graphic Abstract
Source: Asian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research